MX2019000279A - Composiciones y metodos para el tratamiento del cancer. - Google Patents

Composiciones y metodos para el tratamiento del cancer.

Info

Publication number
MX2019000279A
MX2019000279A MX2019000279A MX2019000279A MX2019000279A MX 2019000279 A MX2019000279 A MX 2019000279A MX 2019000279 A MX2019000279 A MX 2019000279A MX 2019000279 A MX2019000279 A MX 2019000279A MX 2019000279 A MX2019000279 A MX 2019000279A
Authority
MX
Mexico
Prior art keywords
formula
cancer
treatment
compositions
methods
Prior art date
Application number
MX2019000279A
Other languages
English (en)
Inventor
Kandula Mahesh
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2019000279A publication Critical patent/MX2019000279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical

Abstract

La invención se refiere a los compuestos o polimorfos, solvatos, enantiómeros, estereoisómeros e hidratos farmacéuticamente aceptables de los mismos. Las composiciones farmacéuticas que comprenden una cantidad eficaz de los compuestos de la Fórmula I, Fórmula II, Fórmula III, Fórmula IV, Fórmula V, Fórmula VI, Fórmula VII y Fórmula VIII y, los métodos para el tratamiento del cáncer y enfermedades infecciosas pueden formularse para administración oral, bucal, rectal, tópica, transdérmica, transmucosa, gragea, aerosol, intravenosa, solución oral, tableta de capa de mucosa bucal, administración parenteral, jarabe o inyección. Dichas composiciones pueden usarse para el tratamiento del cáncer, neoplasias, infecciones y enfermedades de la piel.
MX2019000279A 2016-06-28 2017-05-12 Composiciones y metodos para el tratamiento del cancer. MX2019000279A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201641022026 2016-06-28
IN201641025259 2016-07-22
IN201741006185 2017-02-21
PCT/IB2017/052814 WO2018002739A1 (en) 2016-06-28 2017-05-12 Compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019000279A true MX2019000279A (es) 2019-08-01

Family

ID=60785109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000279A MX2019000279A (es) 2016-06-28 2017-05-12 Composiciones y metodos para el tratamiento del cancer.

Country Status (14)

Country Link
US (2) US10858349B2 (es)
EP (1) EP3452044A4 (es)
JP (1) JP6950972B2 (es)
KR (1) KR102306412B1 (es)
CN (1) CN109414438A (es)
AU (3) AU2017286852B2 (es)
BR (1) BR112018076257A2 (es)
CA (1) CA3027118C (es)
IL (2) IL263563A (es)
MX (1) MX2019000279A (es)
RU (1) RU2770081C2 (es)
SG (1) SG11201810947PA (es)
WO (1) WO2018002739A1 (es)
ZA (1) ZA201808232B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021001652A2 (pt) * 2018-08-03 2021-05-04 Cellix Bio Private Limited composto e composição farmacêutica
EP3679952A1 (en) * 2019-01-10 2020-07-15 Université de Strasbourg Nanoemulsions encapsulating prodrugs
WO2022043902A1 (en) * 2020-08-29 2022-03-03 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents
WO2022049462A1 (en) * 2020-09-05 2022-03-10 Cellix Bio Private Limited Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (es) * 1992-12-18 1995-08-21 Hoffmann La Roche
JPH1192386A (ja) * 1997-09-17 1999-04-06 Nikken Chem Co Ltd ５−フルオロウリジン誘導体を有効成分とする抗癌剤
JP2004505899A (ja) 2000-08-09 2004-02-26 コーロン　インダストリーズ　インク ５’−デオキシ−ｎ−（置換されたオキシカルボニル）−５−フルオロシトシン及びその誘導体、その製造方法、並びに、これを有効性分として含む抗癌剤組成物
EP2647287A1 (en) * 2008-08-01 2013-10-09 Dow AgroSciences LLC Use of 5-fluorocytosine and its derivatives as fungicides
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
WO2015116782A1 (en) * 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
GB201419015D0 (en) * 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds

Also Published As

Publication number Publication date
KR20190034539A (ko) 2019-04-02
KR102306412B1 (ko) 2021-09-28
AU2023208158A1 (en) 2023-08-17
IL280587B (en) 2021-10-31
US20210078983A1 (en) 2021-03-18
BR112018076257A2 (pt) 2019-03-26
ZA201808232B (en) 2019-09-25
RU2770081C2 (ru) 2022-04-14
AU2021203748A1 (en) 2021-07-08
CN109414438A (zh) 2019-03-01
CA3027118C (en) 2023-08-15
EP3452044A1 (en) 2019-03-13
EP3452044A4 (en) 2020-04-22
US10858349B2 (en) 2020-12-08
AU2017286852B2 (en) 2021-05-06
JP6950972B2 (ja) 2021-10-20
CA3027118A1 (en) 2018-01-04
WO2018002739A1 (en) 2018-01-04
AU2017286852A1 (en) 2019-01-17
SG11201810947PA (en) 2019-01-30
IL263563A (en) 2019-01-31
IL280587A (en) 2021-03-25
RU2019100713A3 (es) 2021-02-08
NZ749512A (en) 2021-08-27
RU2019100713A (ru) 2020-07-28
US20190292171A1 (en) 2019-09-26
JP2019519563A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
MX2019007713A (es) Composiciones y metodos para el tratamiento del dolor cronico.
MX2019003912A (es) Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal).
MX2019000279A (es) Composiciones y metodos para el tratamiento del cancer.
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
MX2018009870A (es) Inhibidores de taf1 para la terapia del cancer.
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
WO2014141057A3 (en) Compositions and methods for the treatment of cancer
MX2019006163A (es) Composiciones y metodos para el tratamiento de enfermedades infecciosas orales.
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2019005568A (es) Composiciones y metodos para el tratamiento de polipos gastrointestinales.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2019001360A (es) Composiciones y metodos para el tratamiento de sindrome de intestino irritable.
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
SG10201906474QA (en) Compositions and methods for the treatment of mucositis